Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential biomarker for aspirin use in colorectal cancer therapy.

Nature reviews. Clinical oncology - 1 Jan 2013

Langley Ruth E, Rothwell Peter M

Abstract excerpt

Patients with colorectal cancer with mutated PIK3CA, identified from two large observational cohorts, had increased cancer-specific and overall survival if they used aspirin regularly after diagnosis compared to non-users. No effect of aspirin was seen in patients with wild-type PIK3CA. Mutated PIK3CA might be a useful biomarker to select patients who would benefit from adjuvant aspirin therapy.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents, Non-Steroidal
Share to Aspirin
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Colorectal Neoplasms

Share to Phosphatidylinositol 3-Kinases

Share to Prognosis

Share to Survival Rate

Source

Identifiers

PMID: 23207797
DOI: 10.1038/nrclinonc.2012.216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential biomarker for aspirin use in colorectal cancer therapy.PMID 23207797Read ↗

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.Semantic proximity Read ↗

PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.Semantic proximity Read ↗

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.Semantic proximity Read ↗

Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort StudySemantic proximity Read ↗

Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.Semantic proximity Read ↗

Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.Semantic proximity Read ↗

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.Semantic proximity Read ↗

Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!Semantic proximity Read ↗

Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis.Semantic proximity Read ↗

Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.Semantic proximity Read ↗

Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.Semantic proximity Read ↗

Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.